Prostamax

Source-reported examples · not treatment recommendations

Amount

0.5–1 mg per day

Frequency

Once daily

Cycle / observation period

8–12 weeks; source also mentions 16 weeks

Route / research model

Intramuscular

The source cites preclinical administration. That does not establish a human regimen.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• Prostamax is identified as the short peptide Lys-Glu-Asp-Pro in a primary chromatin study. The selected record includes human-derived cell experiments and rat prostate-tissue cultures. These are relevant laboratory observations, but they do not establish relief of urinary symptoms or treatment of prostate disease in people. ^{[1] [2]}
• A 2004 study examined chromatin in human lymphocytes using thermal measurements. Prostamax exposure changed the distribution and temperatures of features in the heat-response profile. The authors interpreted these observations as changes in chromatin organization. The experiment did not measure urinary function or a prostate-treatment outcome. ^[3]
• The 2006 organotypic-culture study included Prostamax and prostate explants from young and aged rats, alongside other peptide/tissue comparisons. It reported stimulation in the corresponding cultures. This adds tissue-relevant evidence beyond lymphocyte experiments, but it does not establish clinical repair or symptom improvement. ^[2]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 12 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. Original identity and chromatin report
2. original tissue-culture study
3. Original thermal study
4. Modern Research in Inflammation (2013)Further reading · Listed in reference bibliography.
5. Modern Research in Inflammation (2014)Further reading · Listed in reference bibliography.
6. Bulletin of Experimental Biology and Medicine (2004)Further reading · Listed in reference bibliography.
7. Stem Cell Reviews and Reports (2020)Further reading · Listed in reference bibliography.
8. CDCNo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
9. CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
10. CDCGeneral guidance · Listed in reference bibliography.
11. NIBSC (MHRA)Further reading · Listed in reference bibliography.
12. NCBI BookshelfFurther reading · Listed in reference bibliography.
13. CDCGeneral guidance · Listed in reference bibliography.
14. Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.